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Background: Despite several recent subgroup analyses, the perception persists that ACE inhibitors (ACEi) are not effective in African-American (AA) 
patients. No large scale trials have addressed the efficacy of ACEi or angiotensin receptor blockers (ARB) in AA patients concurrently treated with 
beta blockade in all forms of congestive heart failure (CHF).
Methods: In this retrospective study, we review all patients admitted to our medical system over 8.5 years with a left ventricular ejection fraction 
<35%. All patients were concurrently treated with beta-blockers. We use log-rank Mantel-Haenszel analysis to compare AA patients treated with an 
ACEi or ARB to those who were not, with all-cause mortality and hospital readmission for CHF as endpoints. Patients were followed for 1500 days.
Results: We identify 2114 patients who meet our criteria, of whom 211 did not receive an ACEi or ARB, while 1903 did. The ACEi/ARB group had a 
significant improvement in all-cause mortality over the follow-up period. At 1500 days, there was an absolute rate reduction of 34.3% with a number 
needed to treat of 3 (p~0). The ACEi/ARB treatment group had a higher incidence of readmission.
Conclusions: ACE inhibition is an effective treatment in AA patients with CHF, significantly reducing mortality in this population. This study should 
dispel all remaining doubt that this is not a useful modality for treating heart failure in the AA population. These results should be correlated with a 
prospective, randomized control trial.
